Christina M. Hull
Credentials: Human fungal pathogen development and pathogenesis
Position title: Professor (also Professor of Medical Microbiology & Immunology)
Phone: (608) 265-5441
5204B Biochemical Sciences Building
440 Henry Mall, Madison, WI 53706
• B.S. 1992, University of Utah
• Ph.D. 2000, University of California – San Francisco (A.D. Johnson)
• Postdoctoral 2000-2003, Duke University (J. Heitman)
Honors & Awards
• Honors Baccalaureate Award for Graduate Studies, University of Utah, 1992
• Damon Runyon Cancer Research Fund Fellowship, 2001-2003
• Merton Bernfield Memorial Award, American Society for Cell Biology, 2002
• Bell Basic Science Research Award, Duke Comprehensive Cancer Center, 2002
• Armstrong Fellowship, Duke Comprehensive Cancer Center, 2003
• Burroughs Wellcome Career Award in the Biomedical Sciences, 2003-2008
• March of Dimes Basil O’Connor Research Award, 2005-2007
• MERC New Investigator Award, UW Madison, 2005-2007
• Merck Irving S. Sigal Memorial Award, American Society for Microbiology, 2006
• Hartwell Foundation Biomedical Research Award, 2015-2018
Fungi are critical organisms in virtually all ecosystems on Earth, but as a group, they are very poorly understood. The mechanisms by which fungi reproduce and interact with their environments (including human hosts) are largely unknown. Nowhere are the consequences of this lack of understanding more apparent than in human disease. Fungi now represents the fourth most common cause of hospital-acquired infection, and therapeutic options for treating severe disease are extremely limited.
Research in my laboratory focuses on three broad areas: 1) understanding the molecular mechanisms that control fungal development and sporulation, 2) elucidating the basic properties of spores that allow them to be infectious particles, and 3) developing interventions to prevent and/or treat severe fungal diseases.
We use the meningitis-causing environmental fungus Cryptococcus as a model for our studies. Cryptococcus causes several hundred thousand deaths per year worldwide. Among the human fungal pathogens, Cryptococcus is the most amenable to laboratory analysis and represents a relatively facile system for the study of fungal development and virulence.
Using biochemical, genetic, molecular, cell biological, and bioengineering approaches we are determining the basic processes and mechanisms important for Cryptococcus to undergo sexual development (gene regulation, protein-DNA interactions, transcriptional networks), determining the resistance, growth, and molecular properties of spores (cell differentiation, developmental biology), and investigating how spores interact with mammalian hosts in vitro and in mice (infection, virulence).
Perform a customized PubMed literature search for Christina M. Hull
- Hull, C.M., and J. Maher. (2021). Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies. Expert opinion on drug discovery, 16: 1105-1117.
- Reading, J.L., V.D. Roobrouck, C.M. Hull, P.D. Becker, J. Beyens, A. Valentin-Torres, D. Boardman, E.N. Lamperti, S. Stubblefield, G. Lombardi, R. Deans, A.E. Ting, and T. Tree. (2021). Augmented Expansion of Treg Cells From Healthy and Autoimmune Subjects via Adult Progenitor Cell Co-Culture. Frontiers in immunology, 12: 716606.
- Ortiz, S.C., M. Huang, and C.M. Hull. (2021). Discovery of Fungus-Specific Targets and Inhibitors Using Chemical Phenotyping of Pathogenic Spore Germination. mBio, 12: e0167221.
- Ali, N.S., V.N. Sahni, B.C. Ma, D.R. Sahni, C.M. Hull, D.L. Powell, and A.M. Secrest. (2021). Reply to: low response of granulomatous cheilitis to currently established treatments. Journal of the European Academy of Dermatology and Venereology : JEADV, .
- Westerdahl, S., C.M. Hull, J.T. Clarke, C.B. Hansen, and J.L.W. Rhoads. (2021). A single-center, retrospective record review of malignancy prevalence in patients with dermatomyositis with anti-transcription intermediary factor 1γ antibodies via line immunoassay versus immunoprecipitation. Journal of the American Academy of Dermatology, 84: 559-561.
- Truong, A., C.W. Laggis, T.D. Annis, A.M. Secrest, N.F. Fino, D.L. Powell, L.J. Gardner, T. Gregory, C.M. Hull, and B.K.H. Lewis. (2020). Factors associated with follow-up adherence in patients seen at a referral-based dermatology clinic for the homeless. Journal of the American Academy of Dermatology, 83: 629-631.
- Abbott, J., E.H. Kowalski, S. Klein, R. DeShazo, and C.M. Hull. (2020). Iatrogenic calcinosis cutis secondary to calcium chloride successfully treated with topical sodium thiosulfate. JAAD case reports, 6: 181-183.
- Hull, C.M., C.E. Genge, Y. Hobbs, K. Rayani, E. Lin, M. Gunawan, S. Shafaattalab, G.F. Tibbits, and T.W. Claydon. (2019). Investigating the utility of adult zebrafish ex vivo whole hearts to pharmacologically screen hERG channel activator compounds. American journal of physiology. Regulatory, integrative and comparative physiology, 317: R921-R931.
- Ortiz, S.C., M. Huang, and C.M. Hull. (2019). Spore Germination as a Target for Antifungal Therapeutics. Antimicrobial agents and chemotherapy, .
- Hull, C.M., and J. Maher. (2019). Novel approaches to promote CAR T-cell function in solid tumors. Expert opinion on biological therapy, 19: 789-799.